Moteur de recherche d’entreprises européennes
Financement de l’UE (895 500 €) : Élimination et récupération des polluants persistants pharmaceutiques des eaux usées par procédé sélectif sans réactif Hor 31/10/2017 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Élimination et récupération des polluants persistants pharmaceutiques des eaux usées par procédé sélectif sans réactif
Pharmaceutical drugs, characterized by their environmental persistence (e.g. cytostatic drugs [CDs]) have been detected in water bodies (drinking water, groundwater, surface water, and effluent wastewater) at concentrations up to μg/L level. Actual methods for the removal and degradation of CDs, including electrochemical, photochemical, and biological methods have been developed. However, these methods are expensive and sometimes inefficient for CDs complete removal from the treated water. Including the exploitation of previous results from EU funded projects, the goal of project RECOPHARMA is to design, develop, validate and demonstrate a novel process by sequential integration the potentials offered by Molecular Imprinted Polymers (MIPs), Reagentless Thermosorption (RTS), Nanocomposites Functional Materials, Advanced Oxidation Processes, for an effective treatment aiming the recovery of target recalcitrant CDs and degradation of corresponding transformation products or metabolites, working in a continuous operation mode. The suggested approach offers versatile, fast, highly efficient, and low-cost treatment for wastewaters. RECOPHARMA brings together academic research centres and the private sector, with a long-term goal of designing and developing advanced water treatment technologies in the interest of the society and integrate them for demonstration following a circular economy approach. Through the scheduled secondments, the involved staff will perform the required R&I to demonstrate the technical and economic feasibility of the developed process, including the technical formation of specialists as a fundamental activity to project success. The secondments will also enhance the exchange of knowledge, best practices, know-how, innovations, experience, mutual cooperation and culture of work between different organizations, regions and countries through the partners’ well-established reputation as transfer hubs.
| Centro DE Investigacion Y Desarrollo DE Medicamentos | ? |
| Aeris Tecnologias Ambientales SL | 63 000 € |
| Europe for Business Ltd. | 67 500 € |
| Lunds Universitet | 171 000 € |
| Universita Degli Studi Di Udine | 171 000 € |
| Universitat Autonoma de Barcelona | 270 000 € |
| Universite de Pau et des Pays de l'Adour | 153 000 € |
https://cordis.europa.eu/project/id/778266
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Centro DE Investigacion Y Desarrollo DE Medicamentos, Havana, Cuba.
